Harwin Peter Evan's Form 4 filing
Crescent Biopharma, Inc. (CBIO) · filed Dec 8, 2025
- Accession no.
- 0001104659-25-119320
- Filed
- Dec 8, 2025, 4:30 PM ET
- Trade date
- Dec 4, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $18.2M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director, 10% Owner |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director, 10% Owner |
| Fairmount Funds Management LLCCIK 0001802528 | Director, 10% Owner |
| Kiselak TomasCIK 0001830177 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 4, 2025 | Ordinary Shares | PPurchaseAcquired | +1,360,000 | $13.41 | +$18,237,600 | 2,747,866 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 4, 2025 | Ordinary Shares | PPurchaseAcquired | +131,434 | $13.41 | +$1,762,398.51 | 1,768,140 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.